Vertex Pharmaceuticals Increase (decrease) in amount of unrecognized tax benefits remained flat by 0.0% to $36.48M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 61.6%, from $22.58M to $36.48M. Over 2 years (FY 2023 to FY 2025), Increase (decrease) in amount of unrecognized tax benefits shows relatively stable performance with a -3.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests rising tax uncertainty or aggressive tax planning, while a decrease suggests the resolution of past tax uncertainties.
This metric represents the net change in the total reserve for uncertain tax positions during the reporting period. It a...
A standard financial statement disclosure required under accounting standards for income taxes.
other_unrecognized_tax_benefits_period_increase_decrease| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $156.30M | $90.30M | $145.90M |
| YoY Change | — | -42.2% | +61.6% |